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AB TRACT 
Mice have been utilized to develop a simple, rapid, inexpensive. quantitative screening 
procedure for sweat tnhibition b) anticholinergic agents. Graded doses of anticholinergic 
drugs a re injected with a microl iter syringe subcutaneouslv under the plantar foot pads of one 
hind foot of mice. Both hind feet are then coated with a. uspension of starch and castor oil, 
and the mice are stimula ted to sweat by an intraperitoneal injection of 10 mg/kg of 
pilocarpine HCI. Sweating on the treated foot is judged to be inhibited or not inhibited 
relative to the contralateral untreated fooL The median inhibitory concentrations and 95% 
confidence limits are determined by a simple, approximate method. The relative potencies of 
test compounds are expres ed in terms of their ra tios tO a standard, scopolamine HBr. 
Compounds represent ing a wide range of potencies have been screened , and significant 
differences in their sweat inhibiting potencies have been demonstrated . These compounds 
include. in order of decreasing activity: tridihexethyl chloride and (2- [2-methyl-1-pyrrol-
idyl )ethylphenylcyclopentylaceUlte) HCI. which have imilar potencies, 3,3-diphenyl-~­
dimethylpropylamine HCl and hydroxyzine HCI. 
Anticholinergic agents have been used to control 
clinical hyperhidrosis [1 ]. In addition, industrial 
laboratories have expressed an interest in develop-
ing afe and effective topical anticholinergic an-
tiperspirant [2. 3). Thus. the u efulness of a 
uitable procedure to select candidate compounds 
for this purpose has become apparen l. Although 
there are many methods for measuring anticholin-
ergic activitv, most do not gwe direct information 
concerning the sweat-mhibiting potential of a 
compound. MacMillan et al [2) ha,·e described a 
method util izmg topical application to the human 
forearm which employs a mod ification of the Wada 
[41 starch iodine method to grade sweat inhibition 
on a 0 to 4 scale. Although such a method permits a 
rank ordering of effective compounds, it does not 
permit a quantitative description of their relative 
potency. Other methods for studying sweating in 
the human include total body weij!ht loss [51. 
axillary gra\imetric de terminations [3), and resist -
ance hygrometer measurements [6). Quantitat i,·e 
sweat collection under anaerobic conditions has 
been performed in man [7 ], the cat [8 j, and the ra t 
[9 ]. These methods are not ideally suited for 
ant iperspiran t creening smce they are time con-
suming, tediou . and in some cases require the u:.e 
of human subJects. ln addition, procedure which 
involve topical application eliminate from consid -
eration compound which may act upon the cholin-
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ergic receptors of the sweat glands, but which may 
nol reach that site owing to the cutaneous barrier. 
Conceivably, such compounds might be modified 
in a manner which would enhance their percutane-
ous ab orpt ion by conver ion toe ters (2) or by use 
of a percutaneous carrier solvent such as dimethyl-
sulfoxide [10 ]. Thus, the need for a simple. rapid, 
inexpensive screening procedure uti lizing animals 
is evident. 
ln 1968, Hayashi (111 described westing in the 
foot of the mouse detected by the starch- iodine 
technique. H is observations have been utilized by 
us to develop a screening procedure for anticholin -
ergic antiperspirants which procedure can be per-
formed on anaesthetized mice. The criterion for 
the efficacy of a compound i any degree of 
inhibition of the sweating respon e induced by 
pilocarpine HCI evident to the observer. Judging 
the inhibition on a quanta! basis simplifies data 
collect ion and facilitates statistical analysis. 
MATERIALS AND METIIODS 
For the dose-respon11e determmaticm, four or live 
t:roup!o of 5 10 ICRIDUH. male. alhmo mice weighintc 
approximately 20 gm were used. The animals were 
anaest helt.t.ed with 0.20 ml of a 2!)() mg/ml solution of 
ethyl corbamate injected intraperitoneally. Both hind 
feet were pamted with a 2'l solution of todine in ethanol. 
which was permitted to dry. Anticholinergic test solu-
llons. m twofold concentral ion increment • . were injected 
10 5 111 of 0 .9'l . aCI subcutaneously under the plantar 
foot pads of the rit:ht hind feet of 5- 10 mice per 
concentration. The 26 gouge, 2 in. need le of a Hamilton 
LO 11 1 syringe was inserted at the rear of the plantar 
surface and threaded forward. The doRe was delivered 
subcutaneously near the mterdigital foot pads. Subse-
quently, both hind feet were coated with a I I suspension 
of soluble starch in castor oil [12]. At 5 min after test 
solution tnjection, sweating was stimulated by injecting 
-
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each animal intraperitoneally with 0.20 ml of I mg/ml 
pilocarpine H('J (Mann. t\ew York. N. Y. l in 0.9'1- 'aCI. 
The appearance 0f blue-black spots within 5 min after 
. stimulation by pilocarpine wa~ the criterion for ~weating. 
Twn mire per concent ration were injected in the right 
.., foot with 0.9"i NaCI for u~e a~ noninhihited controls. The 
median inhibitory concentration !IC , 0 ) for sweat inhibi-
tion with it ~ 95"; confidence l imit~ was determin£>d 
according tn Litchfield and Wilcoxon p:n The te~t for 
parallelism of slopes between test compounds and the 
s tandard (~cnpolamine H('l) was applied, and potent·y 
ratios relative to the standard, with their confidem·e 
limits. were a lso determined The compound» screenerl 
'Y 
., 
included scopolamine HRr ( l\lann. 'ew Ynrk. ~. Y.l. 
tridihexethyl chloride (Wallace Laboratories. Cranbury. 
t\. .J.). 12- [2-methyl-1-pyrrohd,·l ]ethylphenylcyclopentyl-
acetale HCI (lJ-0;)4,1. UpJOhn Company. Kalamawo. 
Mich.), 3.:1-diphenyl-~-dimethvlpropylamine HCI tThe 
G illelle Re~earch Institute. Rockville. Md.) and hvdrox' -
zine H('l tCharle~ Pfizer & Company. Inc .. :\ew York. 
N. Y.l. 
R£Sl LTS 
Upon injection with pilocarpine HCI. the mice 
began to salivate profusely as well as to sweat 
FIG. I : Sweat res ponsr w pilncarpme HC'I in nun inhibited mouse feel. Left fool unl rea ted. Ri~:ht foot injected with 
5 ~tl of 0.9'' :'-JaCI solution. 
FtG. :!: Sweat re!.ponse in 1 he mouse to pilocarpine HCI in nontrcated control I hot (left 1 and in test loot (right ) 
injected wtth an ant icholinergir cum pound. 
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TABLE 
Effect nf t;e/ected anticholineri/IC compounds on su•Pat inhibit1on in the mou.~e foot 
Compound 
copolamine HBr s 
T 
T 
u 
u 
3 
ridihexethyl chloride 
ridihexethyl chloride 
-0545 ( \Jpjohn) * 
-0545 (Upjohnlt 
, 3-diphenyl-N -dimethyl-
propylamine HC'I 
3 . 3-diphenvl-N -dimethyl-
propylamine HCI 
H 
H 
ydroxyzine H(') 
ydroxyzine JlCI 
Trial' :-.n. nf 
unimaiR 
l 40 
I 45 
2 :t2 
1 40 
2 24 
1 !lO 
2 :i4 
I -18 
2 :38 
IC ,. f ((' .,t 
---
2.:l 10 • M L.R 
t.a 10 • M 1.6 
6.2 10 • M 2.:! 
1.5 10 • M 2.2 
l.!l 10' M 1.6 
a.6 10 3 M 1.6 
6.2 w• M l.!l 
2..1 i'- 10 ' M l.i 
:J.5 ~ 10 ' M 2.0 
Sln1w Pnt<·ncv f Pmencyt fSlopl.'t relntt\'C .tn functiun SCOI><tlamine rntio 
II r-
- - --
2.9 2.8 
3.:1 2.2 1.8 10 t 2.1 
2..t 19 2.8 • ]() ' 2.8 
:).6 2.:1 1.6 10 2 2.6 
1.9 1 1 1.7 10 • 2.1 
2.:1 1 j 6.5 X JW' 2.1 
.., 
:til 3.1 3.8 A 10 . 2..! 
2.8 1.5 9.8 1() -• 2.2 
4.0 :3.2 6.7 " 10-' 2.!i 
• Duplicate trials were performed hy different observers at inter\ ols of se\·eral months. 
t The f-value il; the factor hy whirh the term~. I(' ••· !ilope function onci potPnn ratio are multiplied and divided to • 
obtain their respective 95<;; ronfidencc limits J!3J. 
t (2· [2-methyl-1-pyrrolidvl Jethylphenylcyclopentvlacetate) H('l 
uniformly on the foot pads of both hind feet in 
saline-injected control mice (Fig. ll. Inhibition of 
sweating was evident as a reduction or abbence of 
sweating on the foot injected with the anticholiner-
gic compound. while the contralateral foot sweated 
uniformly (Fig. 2). When very high doses of anti-
cholinergic agents were injected, a systemic effect 
was evident in the form of failure to sweat on the 
noninjected foot as well as on the injected foot. 
The IC 50 values and their 9fi~, confidence limits 
for the standard. scopolamine HBr. and for dupli-
cate trials with four compounds are compared in 
the Table. Scopolamine HBr is the most potent 
sweat inhibitor descnbed here. thllowed by tridi-
hexethvl chloride and U-0545 which have similar 
potencies. Next in potency is 3. 3-diphenyl-l'\-
dimethylpropylamine HCI. The least potent of the 
compounds described is hydroxyzine HCl. 
DISCUSSION 
The mouse foot screen for sweat mhibition hy 
anticholinergic drugs permits the comparison of 
the activity of the inhibitors dirrctly upon the 
sweat glands. bypassing cutaneous barriers. The 
data obtained are superior to the usual rank-order 
estimate of activity provided by most tests for 
sweat inhibition because they permit a determina-
tion of the potency ratio \\ ith respect to a standard. 
Since the test described here is intended only to 
select compounds for further evaluation, many 
considerations which would apply to a definitive 
study of agonist antagonist relationships are not 
relevant. The time interval bet ween test solution 
and pilocarpine HCI administration and between 
pilocarpine HCI injection and reading the sweat 
inhibition is a matter of conventence. II inhihitory 
activity reaches a peak and t.hen dissipates before 
reading the response or if the onset of act ivily is 
very slow. the com pound will be judged to have low 
activity. Also. the duration of inhibition is not 
detected in this test. The pilocarpine HCl dose has 
been selected to be in ex<·ess of the ED ann to ensure 
that failure to sweat is not due to failure to 
stimulate. Mice are anaesthetized in order that the 
test may be performed without the delay and the 
variation tn sweat stimulus due to exercise which 
attends the application of effective restraints . :'-:o 
evidence has been found experimentally or in the 
literal ure that ethyl carbamate acts as a sweat 
inhibitor, nor does the molecule possess a st ructure 
to suggest that it exhibits anticholinergic proper-
ties. The possibility of its synergistic effect with ' 
some of the test compounds is one of the uncertain-
ties which are tolerated in a screening procedure, 
and such problems would he resolved in the course 
of further animal pharmacologic and toxicologic 
in vest iga t ions. 
The mouse foot screen for sweat inhibition can 
be used to select fnr further stud:. suitable com- • 
pounds for the topical or c;ystemtc control of 
hyperhidrosis. 
The authorb wa,h to thank Or Karl Laden for his 
valuable discus.-;ion and cri11c1~m and Dr Robert Gul\'ac-
chini fur hts encourai'(Cment durin!'( the preparation of 
this manuscript. They are inciebted to Dr. Maria Wol 
frum for the ,;ynthesis of :l.:l·diphcnvl-::'\-dimethyl-
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